Literature DB >> 11853692

UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term.

Abby C Collier1, Natalie A Ganley, Malcolm D Tingle, Marion Blumenstein, Keith W Marvin, James W Paxton, Murray D Mitchell, Jeffrey A Keelan.   

Abstract

The activity, expression and localization of the UDP-glucuronosyltransferases (UGTs) were investigated in human placenta at term. UGT activity (measured with the substrate 4-methylumbelliferone (4-MU)) was observed in all 25 placentas sampled and maximum velocity (V(max)) ranged 13-fold from 5.1+/-0.9 to 66.9+/-17.5 nmol/min/mg protein (mean+/-SD). Substrate affinity (K(m)) ranged 5-fold from 246+/-24 to 1124+/-422 microM. Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of the isoforms UGT2B4, 2B7, 2B10, 2B11 and 2B15 was observed in all (12/12) placentas sampled and expression of UGT2B17 was noted in 8/12 placentas. Northern analysis of the UGT2B7 isoform in 12 placentas revealed a 10-fold difference in expression with RT-PCR variability and the 13-fold variation observed in UGT activity. The presence of UGT2B4 and 2B7 proteins (52 and 56kDa, respectively) was demonstrated by Western blotting. The sites of placental UGT2B transcription (in situ hybridization) and protein expression (immunohistochemistry) were located in the syncytium of the placental trophoblasts bordering the placental villi. UGT1A proteins could not be observed with immunohistochemistry or Western blotting and expression could not be observed with RT-PCR. Our discovery of UGT expression and activity at the site of maternal-fetal exchange is consistent with a role for UGTs in detoxification of exogenous and endogenous ligands and the maintenance of placental function through clearance and regulation of steroid hormones.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11853692     DOI: 10.1016/s0006-2952(01)00890-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  33 in total

1.  Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.

Authors:  Zufei Zhang; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2017-01-03       Impact factor: 3.922

Review 2.  Recent advances in simultaneous analysis of bisphenol A and its conjugates in human matrices: Exposure biomarker perspectives.

Authors:  Syam S Andra; Christine Austin; Juan Yang; Dhavalkumar Patel; Manish Arora
Journal:  Sci Total Environ       Date:  2016-08-30       Impact factor: 7.963

3.  Obstetric Obesity is Associated with Neonatal Hyperbilirubinemia with High Prevalence in Native Hawaiians and Pacific Island Women.

Authors:  Luc Ra Rougée; Shogo J Miyagi; Abby C Collier
Journal:  Hawaii J Med Public Health       Date:  2016-12

4.  Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes.

Authors:  Marta Concheiro; Hendreé E Jones; Rolley E Johnson; Robin Choo; Diaa M Shakleya; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2010-04       Impact factor: 3.681

Review 5.  The Placental Barrier: the Gate and the Fate in Drug Distribution.

Authors:  Nino Tetro; Sonia Moushaev; Miriam Rubinchik-Stern; Sara Eyal
Journal:  Pharm Res       Date:  2018-02-23       Impact factor: 4.200

6.  Upregulation of Ugt1a genes in placentas and fetal livers in a murine model of assisted reproduction.

Authors:  A C Collier; K A Milam; L R A Rougée; A Sugawara; Y Yamauchi; M A Ward
Journal:  Placenta       Date:  2011-11-25       Impact factor: 3.481

Review 7.  Placental control of drug delivery.

Authors:  Sanaalarab Al-Enazy; Shariq Ali; Norah Albekairi; Marwa El-Tawil; Erik Rytting
Journal:  Adv Drug Deliv Rev       Date:  2016-08-12       Impact factor: 15.470

8.  Triclosan is a potent inhibitor of estradiol and estrone sulfonation in sheep placenta.

Authors:  Margaret O James; Wenjun Li; David P Summerlot; Laura Rowland-Faux; Charles E Wood
Journal:  Environ Int       Date:  2009-03-18       Impact factor: 9.621

9.  Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.

Authors:  S L Kacinko; H E Jones; R E Johnson; R E Choo; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2008-08-13       Impact factor: 6.875

10.  Assisted reproduction technologies impair placental steroid metabolism.

Authors:  Abby C Collier; Shogo J Miyagi; Yasuhiro Yamauchi; Monika A Ward
Journal:  J Steroid Biochem Mol Biol       Date:  2009-05-03       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.